By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


Company News
Pharmacyclics, Inc. (PCYC) Files Supplemental New Drug Application For IMBRUVICA® For Waldenstrom's Macroglobulinemia 10/20/2014 8:29:51 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Now Approved In Europe for Treatment Of Two Blood Cancers 10/17/2014 8:02:09 AM
Pharmacyclics, Inc. (PCYC) Enters Into Agreement With Roche (RHHBY) To Evaluate IMBRUVICA® And GAZYVA® In Lymphoma And Leukemia 10/16/2014 1:04:05 PM
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), And Janssen Research & Development Announce Clinical Collaboration To Evaluate OPDIVO® (Nivolumab) And IMBRUVICA®(Ibrutinib) In Non-Hodgkin Lymphoma 10/13/2014 8:44:15 AM
Bay Area's Pharmacyclics, Inc. (PCYC) Stock Slumps After Ending Servier Collaboration 9/25/2014 4:52:25 PM
Pharmacyclics, Inc. (PCYC) Reports Second Quarter 2014 Results 8/1/2014 6:51:03 AM
Pharmacyclics, Inc. (PCYC) Announces Date Of Conference Call To Discuss Financial Results For Second Quarter Of 2014 7/29/2014 8:42:20 AM
U.S. FDA Grants Regular (Full) Approval For Pharmacyclics, Inc. (PCYC)'s IMBRUVICA® For Two Indications 7/28/2014 11:32:27 AM
Pharmacyclics, Inc. (PCYC) Release: Supplemental New Drug Application For IMBRUVICA® Accepted By The FDA And Priority Review Granted 6/9/2014 10:51:06 AM
Pharmacyclics, Inc. (PCYC) Appoints Gregory R. Wade To Lead Business Development 5/20/2014 6:37:52 AM